Results 281 to 290 of about 187,908 (321)

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

Association between S-ketamine induced changes in glutamate levels in the pregenual anterior cingulate cortex and plasma brain-derived neurotrophic factor in healthy subjects. [PDF]

Front Psychiatry
Marx L, Sen ZD, Danyeli LV, Li M, Brigadski T, Leßmann V, Walter M.   +6 more
europepmc   +1 more source

Effects of cell therapy on seizures in animal models of epilepsy: Systematic review and meta‐analysis

Epilepsia, EarlyView.
Abstract This study was undertaken to systematically evaluate the efficacy of cell therapy in reducing seizures in animal models of chronic epilepsy. Three databases, Ovid MEDLINE, Ovid Embase, and Web of Science, were searched using predetermined eligibility criteria.
Afaf S. Altalhi, Muhammad S. Javaid, Nigel C. Jones, Kim L. Powell, Patrick Kwan, Terence J. O'Brien, Ana Antonic‐Baker   +6 more
wiley   +1 more source

Dual trajectories of serum brain-derived neurotrophic factor and cognitive function in people living with HIV. [PDF]

Sci Rep
Michael HU, Rapulana AM, Smit T, Xulu N, Danaviah S, Ramlall S, Oosthuizen F.   +6 more
europepmc   +1 more source

Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy

Epilepsia, EarlyView.
Abstract Objective To examine whether initiation of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. Methods We conducted a retrospective cohort study using de‐identified electronic health records from the TriNetX Research Network (January 2003 ...
Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua   +5 more
wiley   +1 more source

Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis. [PDF]

Turk J Med Sci
Erol Yildiz R, Akbayir E, Kizilay T, Ersöz AS, Özkan Yaşargün D, Süer D, Yilmaz V, Tüzün E, Türkoğlu R.   +8 more
europepmc   +1 more source

Meta‐analysis of genetic mapping studies in mice reveals candidate epilepsy modifier genes that are outside the current drug development landscape

Epilepsia, EarlyView.
Abstract Objective Despite decades of development in anti‐seizure medications, ~30% of individuals remain refractory to all treatments, and none of the existing therapies are disease modifying. Identifying targets outside the current preclinical paradigm is critically important.
Giovanna L. Durante, Anna L. Tyler, Rod C. Scott, Amanda E. Hernan, J. Matthew Mahoney   +4 more
wiley   +1 more source

When genetics prevail: brain stimulation fails to overcome learning deficits from brain-derived neurotrophic factor <i>Val66Met</i>. [PDF]

Clin Neurophysiol Pract
Ramasawmy P, Iszak K, Brüshaber S, Kállay V, Ambrus GG, Paulus W, Antal A.   +6 more
europepmc   +1 more source

Ashwagandha (Withania somnifera (L.) dunal) root extract containing withanolide a alleviates depression-like behavior in mice by enhancing the brain-derived neurotrophic factor pathway under unexpected chronic mild stress

Hyeongyeong Kim, Hyeon‐Son Choi, Kisoo Han, Wan‐Sup Sim, Hyung Joo Suh, Yejin Ahn   +5 more
openalex   +1 more source